Ftse Mib
33.809,37
0,19%
DAX
17.963,13
0,23%
S&P 500
5.018,39
0,00%
NASDAQ Composite
15.605,48
0,00%
Bitcoin
58.757,99
0,88%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Incyte Corporation (INCY) Incyte Corporation (INCY) Notizie

INCY

Incyte (INCY)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:INCY
DataOraFonteTitoloSimboloCompagnia
02/05/202414:00Business WireIncyte to Present at Upcoming Investor ConferenceNASDAQ:INCYIncyte Corporation
30/04/202413:00Business WireIncyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical ProgramsNASDAQ:INCYIncyte Corporation
24/04/202400:11Business WireIncyte annonce l'acquisition d'Escient Pharmaceuticals et de son portefeuille d'antagonistes MRGPR oraux premiers de leur catégorieNASDAQ:INCYIncyte Corporation
24/04/202400:01Business WireIncyte gibt Übernahme von Escient Pharmaceuticals und dessen Pipeline oraler First-in-Class-MRGPR-Antagonisten bekanntNASDAQ:INCYIncyte Corporation
23/04/202413:00Business WireIncyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR AntagonistsNASDAQ:INCYIncyte Corporation
11/04/202414:00Business WireIncyte to Report First Quarter Financial ResultsNASDAQ:INCYIncyte Corporation
01/04/202414:30Business WireIncyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast AsiaNASDAQ:INCYIncyte Corporation
29/03/202421:30Business WireIncyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:INCYIncyte Corporation
11/03/202413:57Business WireIncyte gibt neue Daten aus Phase-2-Studie zur Untersuchung von Ruxolitinib-Creme (Opzelura®) bei Patienten mit leichter bis mittelschwerer Hidradenitis Suppurativa bekanntNASDAQ:INCYIncyte Corporation
11/03/202413:57Business WireIncyte annonce de nouvelles données de l’étude de phase 2 évaluant le ruxolitinib crème (Opzelura®) chez les patients atteints d’hidradénite suppurée légère à modéréeNASDAQ:INCYIncyte Corporation
11/03/202411:06Business WireIncyte présente de nouvelles données de l’étude de phase 2 évaluant le povorcitinib chez des patients atteints de prurigo nodulaireNASDAQ:INCYIncyte Corporation
11/03/202410:53Business WireIncyte legt neue brandaktuelle Daten aus Phase-2-Studie zur Prüfung von Povorcitinib bei Patienten mit Prurigo nodularis vorNASDAQ:INCYIncyte Corporation
10/03/202421:05Business WireIncyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis SuppurativaNASDAQ:INCYIncyte Corporation
10/03/202421:05Business WireIncyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo NodularisNASDAQ:INCYIncyte Corporation
04/03/202420:38Business WireDe nouvelles données dérivées du portefeuille dermatologique croissant d’Incyte seront présentées lors de l’assemblée annuelle 2024 de l’American Academy of Dermatology (AAD)NASDAQ:INCYIncyte Corporation
04/03/202420:02Business WireNeue Daten aus dem wachsenden Dermatologieportfolio von Incyte werden bei Jahresversammlung 2024 der American Academy of Dermatology (AAD) präsentiertNASDAQ:INCYIncyte Corporation
04/03/202414:00Business WireNew Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual MeetingNASDAQ:INCYIncyte Corporation
29/02/202416:19Business WireIncyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AINASDAQ:INCYIncyte Corporation
29/02/202413:30GlobeNewswire Inc.Knight Therapeutics Announces Launch of Minjuvi® in BrazilNASDAQ:INCYIncyte Corporation
28/02/202415:11Business WireIncyte annonce que la Food and Drug Administration des États-Unis accorde une évaluation prioritaire à l’axatilimab pour le traitement de la maladie chronique du greffon contre l’hôteNASDAQ:INCYIncyte Corporation
28/02/202413:15Business WireIncyte gibt bekannt, dass die US-Arzneimittelbehörde FDA Axatilimab für die Behandlung der chronischen Graft-Versus- Host-Krankheit als vorrangig eingestuft hatNASDAQ:INCYIncyte Corporation
27/02/202422:08Business WireIncyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host DiseaseNASDAQ:INCYIncyte Corporation
16/02/202422:04Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:INCYIncyte Corporation
16/02/202418:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
13/02/202423:06Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:INCYIncyte Corporation
13/02/202422:03Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:INCYIncyte Corporation
13/02/202413:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INCYIncyte Corporation
13/02/202413:00Business WireIncyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D PrioritiesNASDAQ:INCYIncyte Corporation
06/02/202410:08Business WireIncyte erhält exklusive weltweite Rechte für die Entwicklung und Vermarktung von Tafasitamab (Monjuvi ® )NASDAQ:INCYIncyte Corporation
06/02/202402:55Business WireIncyte obtient les droits exclusifs de développement et de commercialisation du tafasitamab (Monjuvi®) à l’échelle mondialeNASDAQ:INCYIncyte Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:INCY

La tua Cronologia

BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
ISP
Intesa Sanpaolo
BIT
ENEL
Enel
BIT
UCG
Unicredit
BIT
STMMI
ST Microelectronics
BIT
RACE
Ferrari NV
BIT
SPM
Saipem
BIT
BPE
Bper Banca
BIT
AMP
Amplifon
BIT
TEN
Tenaris
BIT
BAMI
Banco BPM
BIT
PRY
Prysmian
BIT
A2A
A2A
BIT
SRG
Snam
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network